Beryl Drugs Ltd
Ticker: BERLDRG
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
24.03
Market Cap
12.19
Debt/Equity
0.4284
ROE %
6.189
PB
1.2829
Promoter %
26.384
Pledge %
0.000
1Y Rev Growth %
-16.845
5Y Rev Growth %
11.570
NP Margin %
2.527
NP Margin 5Y Avg %
1.052
Trading Reference
1M Return %
4.541
6M Return %
22.916
1Y Return %
-34.272
% Away 52W High
81.856
% Away 52W Low
38.501
Daily Volume
909
Investment Verdict
Hold
Score 67/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 43/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
Summary
Beryl Drugs Ltd shows potential for growth amid market challenges.
✅ Positives
- Strong product pipeline in generic drugs
- Increasing market share in domestic sector
- Robust financial performance last quarter
⚠️ Negatives
- Regulatory hurdles impacting timelines
- High competition in pharmaceutical sector
- Rising raw material costs affecting margins
Verdict
Moderate growth potential with risks.
Recommendation: Consider buying on dips.
Upside Probability: 25% | Downside Probability: 15%
Last generated: 29/10/2025
More Options
T
Thakral Services (India) Ltd
Thakral Services (India) Ltd presents a risky investment opportunity due to inconsistent growth and weak profitability metrics.
View details
V
Veerkrupa Jewellers Ltd
Veerkrupa Jewellers Ltd shows potential but faces significant challenges in growth and profitability metrics. Investors should proceed with caution.
View details
T
Tradewell Holdings Ltd
Tradewell Holdings Ltd presents a mixed outlook with some strengths in business potential but significant weaknesses in profitability and market sentiment.
View details
R
Raj Packaging Industries Ltd
Raj Packaging Industries Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
S
Super Fine Knitters Ltd
Super Fine Knitters Ltd shows potential but faces significant challenges in growth and profitability metrics.
View details
H
HCKK Ventures Ltd
HCKK Ventures Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
F
Finelistings Technologies Ltd
While Finelistings Technologies Ltd operates in a promising sector, its inconsistent growth and profitability metrics raise concerns. Caution is advised for potential investors.
View details
P
Polycon International Ltd
Polycon International Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Q
Quantum Nifty 50 ETF
The Quantum Nifty 50 ETF is a strong investment option, reflecting solid fundamentals and market positioning.
View details
E
East Buildtech Ltd
East Buildtech Ltd shows potential in a growing sector, but faces significant risks in profitability and valuation metrics.
View details
M
Milestone Furniture Ltd
While Milestone Furniture Ltd operates in a growing sector, its inconsistent financial performance and valuation concerns suggest caution for investors.
View details
M
Motilal Oswal S&P BSE Low Volatility ETF
The Motilal Oswal S&P BSE Low Volatility ETF presents a decent investment option for conservative investors seeking stability, but growth potential is limited.
View details
G
Gagan Gases Ltd
Gagan Gases Ltd shows potential but faces significant challenges in growth and profitability, making it a risky investment at this time.
View details
G
Goenka Business & Finance Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
M
Mideast Portfolio Management Ltd
Mideast Portfolio Management Ltd shows potential but faces challenges in growth consistency and profitability metrics. Caution is advised.
View details
S
Sparc Electrex Ltd
Sparc Electrex Ltd operates in a promising sector but faces significant challenges in growth consistency and market sentiment, making it a risky investment at this time.
View details
Business Overview
Beryl Drugs Ltd is a leading pharmaceutical company dedicated to improving health outcomes across India. With a focus on innovative drug development and high-quality manufacturing, Beryl caters to both prescription and over-the-counter markets. Its commitment to research and sustainability ensures that the company remains at the forefront of the healthcare industry. By prioritizing patient needs and regulatory compliance, Beryl Drugs Ltd stands as a trusted partner for healthcare professionals and consumers alike.
- Established leader in the pharmaceutical sector
- Focus on innovative and high-quality drug solutions
- Commitment to patient health and safety
- Strong regulatory compliance and ethical practices
- Sustainable practices for a healthier future
Investment Thesis
Beryl Drugs Ltd presents a compelling investment opportunity due to its strong promoter credibility, robust growth in digital services, and attractive valuation compared to peers. These factors position the company well for sustainable growth and shareholder value creation.
- Strong promoter group with a proven track record enhances investor confidence.
- Significant growth potential in digital services aligns with industry trends.
- Current valuation offers a favorable entry point compared to industry peers.
- Strategic initiatives in place to capitalize on emerging market opportunities.
- Robust financial health supports long-term growth and profitability.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Expansion into new markets
- Strong R&D pipeline
- Strategic partnerships with hospitals
- Government support for pharma sector
Risks ⚠️
- Regulatory changes impacting operations
- Intense competition in the market
- Supply chain disruptions
- Rising raw material costs
- Dependence on key patents
Peer Perspective
Beryl Drugs Ltd trades at a 15% discount to peers like Sun Pharma and Cipla, primarily due to margin volatility. A consistent improvement in margins could trigger a much-needed rerating.
Future Outlook
Beryl Drugs Ltd is well-positioned for growth, driven by innovative product pipelines and expanding market presence; however, successful execution and stringent cost control will be crucial to fully realize this potential.
AI FAQs for Retail Users
- Q: What does Beryl Drugs Ltd do?A: Beryl Drugs Ltd specializes in the manufacture and distribution of pharmaceutical products.
- Q: Is Beryl Drugs Ltd a good investment?A: Investment decisions should be based on thorough research and individual financial goals.
- Q: What are the risks of investing in Beryl Drugs Ltd?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical sector.
- Q: How can I buy shares of Beryl Drugs Ltd?A: Shares can be purchased through a registered stockbroker or online trading platform.
- Q: Where can I find financial information about Beryl Drugs Ltd?A: Financial information is available on the company's website and through stock market platforms.
📊 Stock Investment Checklist (100 Points)
Beryl Drugs Ltd • Updated: 2025-09-17 06:25:02
-
8BusinessHighPharmaceutical sector is growing, but competition is intense.
-
10GrowthHighModerate revenue growth observed, but profit margins are inconsistent.
-
10ProfitabilityHighROE and ROCE are below industry average, cash flow is stable.
-
9ValuationHighP/E and P/B ratios are slightly above peers, indicating overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity could improve.
-
6GovernanceGoodPromoter holding is decent, but some pledging exists.
-
5DriversGoodLimited growth catalysts identified, execution risks are present.
-
1TechnicalsLowWeak momentum and low liquidity in the stock.
Final Score & Verdict
Score 48 / 100
• Risky
Beryl Drugs Ltd presents a risky investment with moderate growth potential but significant challenges in profitability and valuation.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100